Poolbeg Pharma PLC (AIM:POLB) announced its annual general meeting (AGM) 2022, with information regarding its annual report and accounts, will be held on 4 April.
The clinical-stage infectious disease pharmaceutical company also posted a voting proxy form to its shareholders.
Those whose distribution in specie shares held in trust by Croft Nominees Ltd also received a voting form of direction with an accompanying letter advising them how to instruct Croft to vote on their behalf.
There will be nine ordinary resolutions as part of the AGM concerning the adoption of the accounts, re-appointment of auditors and fixing of their remuneration, the election/re-election of the company directions, and general authorisation to issue shares, it said.
The special resolutions are in connection with the removal of pre-emption rights on the allotment of new equity shares, cancellation of the share premium account subject to court approval, and permission for and conditions around granting authority for the company to buy back shares, Poolbeg added.
When commenting on its results, Cathal Friel, Poolbeg chairperson said: “As outlined in our results announcement, market conditions have been and remain extremely challenging however we are actively working on creating demonstrable value as we drive the business forward.”
The AGM will be held at 11.00am at DAC Beachcroft LLP offices at 25 Walbrook, London EC4N 8AF.